Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02717611
Title A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications
Therapies
Age Groups: adult
Covered Countries USA | GBR | FRA | ESP | BEL

Facility Status City State Zip Country Details
Research Site Tucson Arizona 85704 United States Details
Research Site Concord California 94520 United States Details
Research Site La Jolla California 92093 United States Details
Research Site Palo Alto California 94304 United States Details
Research Site Washington District of Columbia 20007 United States Details
Research Site Chicago Illinois 60611 United States Details
Research Site Lake Success New York 11042 United States Details
Research Site New York New York 10021 United States Details
Research Site Columbus Ohio 43210 United States Details
Research Site Nashville Tennessee 37203 United States Details
Research Site Houston Texas 77030 United States Details
Research Site Sherman Texas USA United States Details
Research Site Seattle Washington 98108 United States Details
Research Site Seattle Washington 98122 United States Details
Research Site Spokane Washington 99208 United States Details
Research Site Milwaukee Wisconsin 53226 United States Details
Research Site Brugge 8000 Belgium Details
Research Site Bordeaux 33076, FR France Details
Research Site Haifa 31000 Israel Details
Research Site Madrid 28006 Spain Details
Research Site Bournemouth BH7 7DW United Kingdom Details
Research Site Leeds LS9 7TF United Kingdom Details
Research Site Manchester M20 4BX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field